ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 1129
    Development and Validation Of a Rapid Knee Cartilage Quantification Method
  • Abstract Number: 1982
    Development and Validation Of Medication Assessment Tools Specific For Rheumatoid Arthritis
  • Abstract Number: 289
    Development and Validation Of The Cutoff Values For Disease Activity States Of The Three-Item Version Of The Juvenile Arthritis Disease Activity Score
  • Abstract Number: 2836
    Development of a Health Index in Patients With Ankylosing Spondylitis (ASAS HI) – Final Result of a Global Initiative Based On the International Classification of Functioning, Disability and Health (ICF) Guided By Assesment of Spondyloarthritis International Society (ASAS)
  • Abstract Number: 497
    Development Of a Novel Bispecific Therapeutic For Arthritic Diseases
  • Abstract Number: 977
    Development Of a Tool To Assess Internal Medicine Residents’ Confidence In Their Musculoskeletal Examination Skills
  • Abstract Number: 1288
    Development Of Antibodies Specific For Carbamylated Protein Precedes Disease Onset In Mice With Collagen-Induced Arthritis
  • Abstract Number: 2620
    Development Of De Novo Major Involvement During The Follow-Up In Behçet’s Disease
  • Abstract Number: 1028
    Development Of Patient-Reported Outcomes Measurement Information System (PROMIS®) Gastrointestinal (GI) Symptoms Item Bank
  • Abstract Number: 1699
    Development Of Systemic Lupus Erythamatosus Among “Possible Systemic Lupus Erythamatosus ” Patients Seen In Consultation: Long-Term Follow-Up
  • Abstract Number: 2212
    Development Of Tools To Facilitate Shared Decision Making About Medications For Juvenile Idiopathic Arthritis – A Project Of The Pediatric Rheumatology Care and Outcomes Improvement Network
  • Abstract Number: 2116
    Diabetes: A Risk Factor For Poor Function Outcome After Total Knee Arthroplasty
  • Abstract Number: 2244
    Diagnostic Accuracy Of Anti-Ccp Testing For Detecting Prevalent Rheumatoid Arthritis: Results From Screening a  Population Based Cohort
  • Abstract Number: 909
    Diagnostic Autoantibody Signatures Of Rheumatoid Arthritis Patients Identified With a Bead-Based Assay Approach
  • Abstract Number: 309
    Diagnostic Delay Of Even More Than 6 Months Contributes To Poor Radiographic and Functional Outcome In Psoriatic Arthritis
  • « Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 193
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology